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Abstract
BACKGROUND: The coronary slow flow phenomenon (CSFP) is believed to be affected by endothelial dysfunction 
ruled by renin, angiotensin, aldosterone, and the angiotensin-converting enzyme (ACE). The gene of ACE has been 
characterized in humans by a major insertion (I)/deletion (D) polymorphism. Serum ACE levels were associated with 
I/D polymorphism in the ACE-encoding gene.
AIM: This study explored and analyzed the role of ACE gene polymorphism risk factors with the incidence of CSFP 
in the population of South Sumatra, Indonesia.
METHODS: This study was a cross-sectional analytic observational study. A total of 112 CSFP and non- CSFP 
patients participated in this study. Blood was obtained from the study subjects then processed. Angiotensin I and 
aldosterone levels were examined using the enzyme-linked immunosorbent assay. The Judkins method was used 
in the assessment of coronary angiography, which was carried out through the femoral artery. For the examination 
of ACE I/D polymorphisms, genome deoxyribonucleic acid was extracted from blood cells (leukocytes), using the 
Wizard’s purification system and examined using the polymerase chain reaction method. All data were evaluated 
through the Chi-square test, two samples t-test, and Mann–Whitney U-test. All tests used two-sided significance and 
p < 0.05 was considered statistically significant.
RESULTS: ACE I/D gene polymorphism possessed a significant effect in increasing the risk of CSFP. Genotype II 
polymorphism increased the risk of CSFP as much as 6.9 times compared to individuals with ID/DD genotype. 
The existence of allele I increased the risk of CSFP 5.7 times compared to allele D. Levels of angiotensin I and 
aldosterone were increased significantly in patients with CSFP.
CONCLUSION: ACE I/D gene polymorphism possessed a significant effect in increasing the risk of CSFP. Genotype 
of II was the risk factor for the development of CSFP in population of South Sumatra, Indonesia.
Introduction
The coronary slow flow phenomenon (CSFP) 
is a clinical angiographic disorder that is characterized 
by late filling of the distal coronary artery during 
catheterization of the coronary artery using contrast, 
which causes symptoms of coronary artery stenosis. 
Although this angiographic disorder has been known for 
almost five decades, the pathological mechanism is still 
unclear and not yet comprehensively known. CSFP has 
serious clinical implications related to the initiation of 
myocardial ischemia, arrhythmias, cardiac death, and 
recurrent acute coronary syndromes. Cardiovascular 
disorders caused by CSFP will cause problems and 
require substantial funds for the management and 
rehabilitation of patients. This is further exacerbated 
by the late diagnosis of CSFP. In general, patients are 
known to experience CSFP after coronary syndrome 
disorder is encountered and after an invasive action 
in the form of cardiac catheterization. Exploration of 
pathomechanism and molecular markers related to 
CSFP is required, to determine the biological changes 
of this disorder that occurs before the emergence of 
cardiovascular disorders [1].
Endothelial dysfunction of coronary artery is 
believed to play an important role in the pathomechanism 
of CSFP. Increased coronary microvascular tone and 
vasomotor dysregulation are the basis for coronary 
endothelial dysfunction. The renin–angiotensin–
aldosterone system (RAAS) plays a role in the regulation 
of vascular and microvascular tone, including coronary 
artery. This system consists of several proteins, namely, 
renin, angiotensin, aldosterone, and the angiotensin-
converting enzyme (ACE). ACE is one of the important 
regulators in the RAAS system. This enzyme plays a role 
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in the conversion of angiotensin I protein to angiotensin 
II, then aldosterone activation occurs which will be 
followed by sodium and water retention in the kidney 
tubules. This will cause an increase in intravascular 
volume, an increase in cardiac output, an increase 
in blood pressure, and an increase in vascular and 
microvascular tone, including coronary artery [2], [3].
Central dogma states that in every expression 
of a protein, it will definitely be preceded by the process 
of transcription of the protein-coding gene, then followed 
by the translation process to produce the target protein. 
The same applies to ACE enzymes. The expression of 
this enzyme is influenced by the enzyme-coding gene. 
Changes that occur in the enzyme-coding gene will cause 
changes in enzyme levels, which of course greatly affect 
the function and role associated with the ACE enzyme. 
The gene of ACE is located on chromosome 17 and has 
been characterized in humans by a major insertion (I)/
deletion (D) polymorphism consisting of the presence of I 
or an absence of D of a 287-base pairs repeat sequence 
within intron 16. Serum ACE levels were associated 
with I/D polymorphism in the ACE-encoding gene. The 
genotype of DD is associated with increased serum 
ACE level, compared to genotype of II. The increasing 
level of ACE increases conversion of angiotensin I to 
angiotensin II and activates signaling pathway from 
inflammation, oxidative stress, and increased vascular 
and cardiovascular tone. Aldosterone is one of the other 
proteins that regulated the rigidity of vascular tone by 
increasing the accumulation of fibrotic tissue and is 
responsible in endothelial dysfunction [4], [5], [6], [7], [8].
This study explored and analyzed the role of 
ACE gene polymorphism risk factors with the incidence 
of CSFP in the population of South Sumatra, Indonesia. 
In addition, this study was the pilot study related to the 
exploration of the role of ACE gene polymorphisms in 
the population of South Sumatra, Indonesia.
Methods
Study design
This study was a cross-sectional analytic 
observational study. Analysis of the role of the ACE 
gene polymorphism, sociodemography, and history of 
metabolic and laboratory related metabolic disorders 
with the incidence of CSFP was carried out in this study.
Study subjects
A total of 112 study subjects (CSFP = 54 
subjects and non-CSFP = 58 subjects) participated in 
this study. The study subjects were patients undergoing 
coronary angiography with suspected coronary arterial 
disease, within the period of May 2018–December 
2018, at Dr. Moh. Hoesin General Hospital, Palembang, 
Indonesia. All study subjects possessed normal 
coronary angiographic result and no atherosclerotic 
lesions were found in coronary arteries; however, there 
was a slowdown in coronary flow rates. Each study 
subject had a history of chest pain that resembled 
angina symptoms based on myocardial perfusion or 
treadmill test. Subjects who were taking vasoactive 
drugs were not included in this study. Every patient 
had taken informed consent related to the willingness 
to participate in the study and various risks that might 
occur during the study. This study had obtained ethical 
approval from the Ethics Committee of the Faculty 
of Medicine, Universitas Sriwijaya/Dr. Moh. Hoesin 
General Hospital (No.231/kptfkunsri-rsmh/2018). 
Every study subject who had agreed to take part in this 
study underwent anamnesis, physical examination by 
cardiologist followed by laboratory examination and 
coronary angiography by cardiologist were performed.
Biochemical parameters assay
Blood was obtained from each study subject 
after 10 h of fasting. In the process, the serum was first 
separated by centrifuge (Biorad®) at a speed of 5000 rpm, 
temperature of 25°C, for 20 min. Then, the supernatant 
was separated from the pellet, stored at −80°C. 
Angiotensin I and aldosterone levels were examined 
using the enzyme-linked immunosorbent assay (ELISA) 
method using the human ELISA kit (Cloud-Clone®). 
A total of 10 μl samples from each study subject were 
included in the microplate well, then incubated for 30 min, 
at 37°C. The microplate was then washed with a washing 
solution on Immuno Washer (Biorad®). Next, conjugated 
horseradish peroxidase was added to each microplate 
and incubation was again performed. The microplate was 
then added with chrom A and chrom B and reincubated 
for 15 min. Then, a stop solution was added to the 
microplate and an optical density (OD) value was read 
from the microplate on the ELISA reader (Biorad®). The 
next step was to convert OD values into angiotensin I and 
aldosterone levels using standard curves.
Angiographic examination
The Judkins method was used in the 
assessment of coronary angiography, which was carried 
out through the femoral artery. All study participants 
were given iopromide (Ultravist 370, Schering AG, 
Berlin, Germany) as a contrast medium. All participants 
underwent assessment for slow coronary flow through 
coronary angiography; total frame cine (TFC) was used 
to measure the coronary flow rate of each patient. To 
ensure that coronary flow was objectively quantified, 
two separate doctors with no information of the patients 
determined coronary flow through TFC. With TFC, the 
operator recorded the number of cine frames (taken 
at 30 frames per second) needed so that the contrast 
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was at the level of the normal distal coronary landmark 
in the following arteries: Left circumflex artery (LCX), 
descending left anterior (LAD), and right coronary artery 
(RCA). Predetermined distal landmarks were distal 
bifurcations of LAD, commonly referred to as “pitchfork” 
or “whale’s tail,” distal bifurcation segments with the 
longest total distance for LCX, and the first branch of 
the posterolateral artery for RCA. The accepted mean 
for normal coronary arteries was 22.2 ± 4.1 frames for 
LCX, 36.2 ± 2.6 frames for LAD, and 20.4 ± 3 frames for 
RCA. TFC for LAD is often the highest of the coronary 
arteries because it is the longest; therefore, TFC for 
LAD must be corrected by dividing it by 1.7.
ACE gene polymorphism assay
For the examination of ACE I/D polymorphisms, 
genome deoxyribonucleic acid (DNA) was extracted 
from blood cells (leukocytes), using the Wizard’s 
purification system (Promega Inc.®) following the 
manufacturer’s instructions. ACE I/D polymorphisms 
were examined using the polymerase chain reaction 
(PCR) method.
Briefly, ACE was obtained through a separate 
reaction, using oligonucleotides. The primary PCR was 
5’GCCCTGCAGGTGTCTGCAGCATGT3’ (forward 
primer) and 5’GGATGGCTCTCCCCGCCTTGTCTC3’ 
(reverse primer). The final volume of the PCR 
reaction mixture was 20 μL containing 1 mM of each 
primer (Invitrogen®), 1.5 mM MgCl2, 0.2 mM of each 
deoxynucleoside triphosphate – dNTp, 2.5 μL of 10 × 
PCR buffer, and 0.5 U of Taq polymerase (Invitrogen®). 
Amplification was carried out in a thermocycler (Biorad®) 
with an initial denaturation step at 94°C for 2 min 
followed by 40 cycles consisting of denaturation at 
94°C for 10 s, annealing at 60°C for 30 s, and extension 
at 72°C for 30 s. PCR products were separated in 8% 
polyacrylamide gels and DNA was visualized with silver 
nitrate. This gel was made with 15 mL of polyacrylamide 
solution, 129 μL of ammonium persulfate, and 15 μL of 
N,N,N’,N’-Tetramethylethylenediamine. DNA fragments 
were 190 bp for D allele and 490 bp for I allele. 
Fragments displayed in the gel were permitted to verify 
if the patient was heterozygous (ID: 490 bp/190 bp) or 
homozygous (II: 490 bp and DD: 190 bp). DNA from 
previously typed individuals was included in each set of 
samples analyzed as control of enzyme activity.
Statistical analysis
All data were evaluated using the SPSS software 
(version 24.0 for Windows, Inc., Chicago, Illinois, United 
States). Continuous variables were presented as mean 
and standard deviation, while categorical variables were 
presented as percentages and analyzed through the Chi-
square test. The Kolmogorov–Smirnov test was used to 
determine whether the data were normally distributed. 
Continuous, numerical, and normal distributed variables 
underwent univariate analysis with two samples t-test, 
while those without normal distribution were analyzed 
with the Mann–Whitney U-test. All tests used two-sided 
significance and p<0.05 was considered statistically 
significant.
Results
Clinical characteristics
All important clinical parameters of the study 
subjects are listed in Table 1. There were no significant 
differences between CSFP and non-CSFP regarding 
gender, age, presence of hypertension, smoking 
Table 1: Demographic and clinical characteristics of the study 
participants
Variables CSFP (n=54) Non-CSFP (n=58) p value
Age, years 53±12 54±11 0.84
Male gender, n 29 (53.7%) 31 (53.4%) 0.79
BMI, kg/m2 31±8 29±9 0.71
Hypertension, n 19 (35.2%) 22 (37.9%) 0.81
Diabetes mellitus, n 21 (38.9%) 23 (39.7%) 0.76
Hyperlipidemia, n 10 (18.5%) 12 (20.7%) 0.83
Cigarette smoking, n 16 (29.6%) 17 (29.3%) 0.68
Family history of CAD, n 10 (18.5%) 9 (15.5%) 0.77
Fasting glucose, mg/dL 112±21 100±19 0.61
Total cholesterol, mg/dL 178±23 182±21 0.73
Triglycerides, mg/dL 147±67 135±56 0.67
HDL cholesterol, mg/dL 45±11 43±12 0.68
LDL cholesterol, mg/dL 117±21 120±19 0.54
TIMI frame count measurements
LAD 60±28 29±7 0.001
LAD (corrected) 35±17 17±4 0.001
LCX 29±11 19±3 0.001
RCA 41±23 19±5 0.001
Mean 35±12 19±3 0.001
The length of epicardial coronary arteries
LAD, mm 170±20 170±19 0.73
LCX, mm 127±30 124±29 0.67
RCA, mm 183±39 166±32 0.87
Diameters of coronary arteries
LAD, mm 3.96±0.66 3.58±0.66 0.021
LCX, mm 3.66±0.61 3.23±0.62 0.041
RCA, mm 3.71±0.81 3.11±0.31 0.003
Coronary flow velocities
LAD, mm/s 102.8±47.0 186.8±57.0 0.001
LCX, mm/s 148.7±59.6 203.7±60.6 0.001
RCA, mm/s 165.9±73.9 281.9±76.9 0.001
Data were presented as mean±SD, median (interquartile range) and as number (percentage). *Student’s 
t-test, Mann–Whitney U-test and Chi-square test; CSFP: Coronary slow flow phenomenon, Non-
CSFP: Non-coronary slow flow phenomenon, BMI: Body mass index, CAD: Coronary artery disease, 
HDL: High-density lipoprotein, LDL: Low-density lipoprotein, TIMI: Thrombosis in myocardial infarction, 
LAD: Left anterior descending artery, LCX: Left circumflex artery, RCA: Right coronary artery. 
history, and the presence of diabetes (p > 0.05). In 
addition, there were no differences in lipid parameters 
or glucose values (after fasting) between the two 
groups (p > 0.05).
TFC
CSFP patients significantly displayed increased 
TFC in all three main coronary arteries compared to 
controls (p < 0.05). While there was no difference in 
blood vessel length between CSFP and non-CSFP, 
CSFP patients possessed coronary arteries that were 
significantly larger in size than non-CSFP, whereas 
non-CSFP showed significantly increased coronary 
flow rates compared to CSFP group (p < 0.05).
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Role of ACE gene polymorphism, level of 
angiotensin I and aldosterone
This study showed that the ACE I/D gene 
polymorphism possessed a significant effect in increasing 
the risk of CSFP. Genotype II polymorphism increased 
the risk of CSFP as much as 6.9 times compared to 
individuals with ID/DD genotype. The existence of allele I 
increased the risk of CSFP 5.7 times compared to allele 
D (Table 2). The PCR was shown in Figure 1.
Figure 1: Angiotensin-converting enzyme gene polymerase chain 
reaction. M: Marker; 1: Genotype DD; 2: Genotype II
Levels of angiotensin I and aldosterone were increased 
significantly in patients with CSFP. These results 
indicated increased activity of the RAAS activity in 
patients with CSFP (Table 2).
Discussion
Coronary artery disease is a polygenic 
disease that involves complex interactions between 
several pathophysiological pathways with several 
genes and environmental risk factors. This study 
analyzed several cardiovascular risk factors in patients 
with CSFP. Abnormal processes such as damage 
to the arterial wall, metabolic disorders, oxidative 
stress, and endothelial dysfunction can cause arterial 
sclerosis, coronary artery lesions, and an increased 
risk of developing atheromatous plaque. This study 
revealed a strong association between ACE I alleles, 
in general, and genotype II, in particular, with CSFP 
risk. Other studies related to the role of ACE I/D gene 
polymorphisms were quite varied. Some studies 
showed no significant association of ACE I/D gene 
polymorphism, while other studies showed different 
results from this study. Other studies related to ACE 
I/D gene polymorphism exhibited that the D allele 
increased the risk of CSFP. These ethnic and racial 
differences affected the genotypic variation of each 
individual. This finding became interesting, due to in 
Indonesia’s South Sumatra population, the ACE I/D 
gene polymorphism that acted as a risk factor was 
allele I, not D. Various studies suggested that the main 
coronary risk factor was associated with coronary 
endothelial dysfunction even before stenosis lead 
to the concept that endothelial dysfunction occurred 
in the early stages of atherosclerosis [3], [9], [10], [11]. 
The ACE I/D polymorphism has been implicated in 
the pathogenesis of atherosclerosis and plays an 
important role in endothelial function. ACE, a key 
enzyme in the RAAS system, converts angiotensin 
I into a powerful angiotensin II vasoconstrictor. The 
chronic effect of higher angiotensin II levels in the 
ACE D allele carrier compared with angiotensin I 
allele carriers may associate with the development 
and/or progression of atherosclerosis. Increased 
ACE activity will increase angiotensin II, affecting 
cell growth and proliferation by stimulating various 
cytokines and growth factors that cause endothelial 
dysfunction by reducing the bioavailability of nitric 
oxide. Increased ACE expression in macrophages 
and smooth muscle cells of coronary artery plaque 
was previously reported to indicate that ACE activity 
in the lesion contributed greatly to the development of 
atherosclerosis [11], [12].
CSFP possibly occurs in coronary vessels 
with no atherosclerotic change in coronary 
angiography. The coronary blood flow may be 
normal in patients with atherosclerotic changes. 
Other studies showed DD genotype might influence 
Table 2: Distribution of ACE I/D, angiotensin I, and aldosterone in CSFP
Distribution of ACE I/D CSFP (n=54), n (%) Non-CSFP (n=58), n (%) OR (95% CI) p value
DD 5 (9.2) 6 (10.3) 0.08 (0.03–0.28) 0.001
ID 11 (20.4) 29 (50) 0.29 (0.19–0.46) 0.001
II 38 (70.4) 23 (39.7) 6.9 (4.4–10) 0.001
I 87 (80.5) 75 (64.6) 5.7 (3.6–7.8) 0.001
D 21 (19.5) 41 (35.4)
Level of angiotensin I and aldosterone CSFP (n=54), Mean (pg/mL)±SD Non-CSFP (n=58), mean (pg/mL)±SD p value
Angiotensin I 234.6±25.7 102.5±11.6 0.001
Aldosterone 367.9±34.4 231.6±27.9 0.001
Data were presented as mean±SD, and number (percentage); ACE I/D: Angiotensin-converting enzyme insertion/deletion, I: Insertion, D: Deletion, Non-CSFP: Non-coronary slow flow phenomenon, CSFP: Coronary slow 
flow phenomenon, OR: Odds ratio, CI: Confidence interval.
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the development of CSFP. The ACE activity was 
higher in patients with DD genotype. Serum ACE 
level was associated with I/D polymorphism in the 
ACE-encoding gene. Genotype of DD exhibited 
increased serum ACE level, compared than 
genotype of II. The increasing level of ACE was 
associated with activated conversion of angiotensin 
I to angiotensin II and activated signaling pathway 
from inflammation, oxidative stress, and increased 
vascular and cardiovascular tone. Aldosterone is 
one of the other proteins that regulate the rigidity of 
vascular tone by increasing accumulation of fibrotic 
tissue and is responsible in endothelial dysfunction. 
The result of this study was different with the previous 
studies [1], [13], [14]. The study showed II genotype 
was the risk factor in CSFP patients. The ACE 
activity was lower in patients with II genotype. Serum 
ACE levels were associated with I/D polymorphism 
in the ACE-encoding gene. Genotype of II exhibited 
decreased serum ACE level, compared to genotype 
of DD. The decreasing level of ACE was associated 
with deactivated conversion of angiotensin I to 
angiotensin II. However, we hypothesized that 
there was another signaling pathway that would be 
responsible for the development of CSFP. A non-
ACE pathway probably played a role in a conversion 
of angiotensin I to angiotensin II and increment of 
aldosterone [15], [16].
Conclusion
ACE I/D gene polymorphism possessed 
a significant effect in increasing the risk of CSFP. 
Genotype of II was the risk factor for the development 
of CSFP in population of South Sumatra, Indonesia.
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